Bristol-Myers Squibb BMY Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| Abraxane | $313M-14.9% | $368M-19.7% | $458M-28.1% | $637M-16.5% | $763M-12.8% | |
| Breyanzi | $1.51B+10.9% | $1.36B+10.5% | $1.23B+12.3% | $1.09B+21.2% | $903M+20.9% | |
| Camzyos | $1.22B+14.5% | $1.07B+14.0% | $938M+17.5% | $798M+17.9% | $677M+12.5% | |
| Cobenfy | $184M+18.7% | $155M+34.8% | $115M+59.7% | $72M+94.6% | $37M+270% | |
| Eliquis | $15.02B+4.0% | $14.44B+1.8% | $14.19B+5.5% | $13.44B+2.0% | $13.18B-1.2% | |
| Krazati | $207M+1.0% | $205M+9.0% | $188M+11.2% | $169M+10.5% | $153M+21.4% | |
| Opdivo Qvantig | $393M+64.4% | $239M+125% | $106M+172% | $39M+333% | $9M— | |
| Opdivo | $9.93B-1.2% | $10.05B+2.2% | $9.84B+1.8% | $9.66B+1.8% | $9.49B+2.0% | |
| Opdualag | $1.23B+3.6% | $1.19B+8.8% | $1.09B+6.5% | $1.02B+5.0% | $974M+5.0% | |
| Orencia | $3.75B+1.3% | $3.71B+0.2% | $3.7B+0.8% | $3.67B+0.4% | $3.65B-0.8% | |
| Other Growth products | $2.1B+3.7% | $2.03B+0.4% | $2.02B+3.6% | $1.95B+6.7% | $1.83B+11.1% | |
| Other Legacy products | $755M-5.4% | $798M-6.0% | $849M-5.4% | $897M+0.1% | $896M-3.1% | |
| Pomalyst/Imnovid | $2.59B-5.3% | $2.73B-4.6% | $2.86B-7.2% | $3.09B-7.5% | $3.34B-5.8% | |
| Reblozyl | $2.4B+3.3% | $2.33B+5.4% | $2.21B+8.2% | $2.04B+7.5% | $1.9B+7.0% | |
| Revlimid | $2.36B-19.9% | $2.95B-20.0% | $3.69B-18.5% | $4.53B-10.2% | $5.04B-12.7% | |
| Sotyktu | $304M+4.8% | $290M+0.7% | $288M+5.1% | $274M+6.6% | $257M+4.5% | |
| Sprycel | $392M-20.6% | $494M-19.3% | $612M-21.8% | $783M-28.0% | $1.09B-15.5% | |
| Yervoy | $2.93B+0.9% | $2.9B+4.9% | $2.77B+3.6% | $2.67B+3.8% | $2.57B+1.6% | |
| Zeposia | $588M+1.9% | $577M+0.2% | $576M+2.5% | $562M-0.2% | $563M-0.5% | |
| Total Revenues by Geography | ||||||
| International | $14.16B+2.4% | $13.83B+1.8% | $13.59B+1.6% | $13.38B+2.0% | $13.12B-0.6% | |
| Other | $1.13B+3.6% | $1.09B-3.6% | $1.13B+1.7% | $1.11B+9.3% | $1.02B+1.9% | |
| United States | $33.19B-0.3% | $33.28B-0.1% | $33.32B+0.3% | $33.22B-0.8% | $33.5B-1.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bristol-Myers Squibb break its business down?
- Bristol-Myers Squibb (BMY) reports total revenues by product across 20 parts — Abraxane, Breyanzi, Camzyos, Cobenfy and Eliquis. Each is extracted from the segment footnotes and tracked over time.
- Where does Bristol-Myers Squibb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bristol-Myers Squibb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
